Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells
- Author:
Boonyakorn BOONSRI
1
;
Kiren YACQUB-USMAN
;
Pakpoom THINTHARUA
;
Kyaw Zwar MYINT
;
Thannicha SAE-LAO
;
Pam COLLIER
;
Chinnawut SURIYONPLENGSAENG
;
Noppadol LARBCHAROENSUB
;
Brinda BALASUBRAMANIAN
;
Simran VENKATRAMAN
;
Isioma U. EGBUNIWE
;
Dhanwant GOMEZ
;
Abhik MUKHERJEE
;
Supeecha KUMKATE
;
Tavan JANVILISRI
;
Abed M ZAITOUN
;
Thiti KUAKPAETOON
;
Rutaiwan TOHTONG
;
Anna M GRABOWSKA
;
David O. BATES
;
Kanokpan WONGPRASERT
Author Information
- Publication Type:Original Article
- From:Cancer Research and Treatment 2021;53(2):457-470
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:The potential of members of the epidermal growth factor receptor (ErbB) family as drug targets in cholangiocarcinoma (CCA) has not been extensively addressed. Although phase III clinical trials showed no survival benefits of erlotinib in patients with advanced CCA, the outcome of the standard-of-care chemotherapy treatment for CCA, gemcitabine/cisplatin, is discouraging so we determined the effect of other ErbB receptor inhibitors alone or in conjunction with chemotherapy in CCA cells. Materials and Methods ErbB receptor expression was determined in CCA patient tissues by immunohistochemistry and digital-droplet polymerase chain reaction, and in primary cells and cell lines by immunoblot. Effects on cell viability and cell cycle distribution of combination therapy using ErbB inhibitors with chemotherapeutic drugs was carried out in CCA cell lines. 3D culture of primary CCA cells was then adopted to evaluate the drug effect in a setting that more closely resembles in vivo cell environments.
Results:CCA tumors showed higher expression of all ErbB receptors compared with resection margins. Primary and CCA cell lines had variable expression of erbB receptors. CCA cell lines showed decreased cell viability when treated with chemotherapeutic drugs (gemcitabine and 5-fluorouracil) but also with ErbB inhibitors, particularly afatinib, and with a combination. Sequential treatment of gemcitabine with afatinib was particularly effective. Co-culture of CCA primary cells with cancer-associated fibroblasts decreased sensitivity to chemotherapies, but sensitized to afatinib. Conclusion Afatinib is a potential epidermal growth factor receptor targeted drug for CCA treatment and sequential treatment schedule of gemcitabine and afatinib could be explored in CCA patients.
